All News
Blood Flow Restriction to Reduce Pain in Knee OA
d
MedPage Today
A technique now widely used in sports medicine to speed recovery from leg injuries helped reduce symptoms and improve function in people with osteoarthritis (OA) of the knee, a randomized trial showed.
Read Article
Participation is Up! (1.31.2025)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. We also have two call-in cases on "Ask Cush Anything".
Be sure to join in the fun at RNL 2025 next weekend - Gong Show Karaoke; what will you sing?
Read Article
AGA Guideline: Prevention and Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals
The American Gastroenterology Association has published its revised clinical practice guidelines for the prevention and treatment of hepatitis B virus (HBV) reactivation in at-risk patients, particularly those with immune-mediated disease, receiving immunomodulatory therapy and steroids.
Read Article
UK NHS 2023-24 figures show hospitalization for SLE is 8X more common in blacks (62.6 per 100,000) compared to white SLE (7.8/100K) and Asian SLE (26/100K), Lupus hospitalizations risen 50% in 4 yrs (6,334 to 8,006 in 2023-24). Is this “stark” inequality from delayed Dx?… https://t.co/NDdIkWKZy5 https://t.co/E4Fmvz9uLn
Dr. John Cush RheumNow ( View Tweet)
RHEUMS! Please check out this important Survey on Cannibis/THS/CBD use in Rheumatology. This is a short survey (Ive done it) from the Rheumatology Research Foundation, FORWARD and the National Databank folks. We need to know more here; especially from you1 Link:… https://t.co/0KYbgqvceq https://t.co/JeO8hV0luB
Dr. John Cush RheumNow ( View Tweet)
FDA has approved Journavx (suzetrigine) 50 mg tablets, 1st in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx reduces pain by targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system, before pain signals… https://t.co/xKy7JY7pPr https://t.co/VYrDMQcjHc
Dr. John Cush RheumNow ( View Tweet)
Cross-sectional study of 50 SLE patients, 24% had fibromyalgianess, and 18% experienced widespread pain. Fibromyalgianess in SLE patients primarily reflects heightened pain sensitivity and symptom severity rather than SLE disease activity. https://t.co/oLYc4IsIpN https://t.co/eHVIe9OXVF
Dr. John Cush RheumNow ( View Tweet)
Screening for #RA-Machine learning algorithm applied to primary healthcare pts shown to correctly identify early RA based on 11 features (RF, CRP, ESR, SUA, HB, PLT, AMS, age, SJC TJC, deformity) w/ 96% specificity, 96% sensitivity, 96% AUC. https://t.co/Q25yvDwdJZ https://t.co/CTESAl6hSf
Dr. John Cush RheumNow ( View Tweet)
Infectious Sacroiliitis
A large Chinese cohort study of patients with infectious sacroiliitis (SI) suggests that CT-guided biopsy of the sacroiliac joint is necessary to properly identify the infectious pathogen leading to SI.
https://t.co/GYI8iz0rOS https://t.co/3wQR47Wd4g
Dr. John Cush RheumNow ( View Tweet)
Orthotics in Rheumatoid Arthritis
RA is a chronic inflammatory disease affecting synovial joints, often in the hands and feet. Due to its progressive inflammatory nature, RA can lead to impairment of function, reduced quality of life, significant joint pain, disability, and… https://t.co/Tqf5YsSFX3 https://t.co/imnPyNXXkq
Dr. John Cush RheumNow ( View Tweet)
Adalimumab Withdrawal in Uveitis Patients
Adalimumab is an effective treatment for JIA-associated uveitis and has been FDA approved for such use - but for how long and can the drug be withdrawn? An adalimumab (ADA) withdrawal trial has shown recurrence of uveitis, arthritis, or… https://t.co/J1CRgC3GJz https://t.co/8eOSvl5zZm
Dr. John Cush RheumNow ( View Tweet)
JAMA Case: 58-Year-Old Woman With Urticaria, Fever, and Joint Pain. 2 yrs daily fatigue, arthralgia (hands, feet, shoulders, knees), myalgia, intermittent fevers (>38.5°C). NL CBC, CRP 20.9 mg/L. negative dsDNA, ANCA, ENA, nl LFTs. What do you do next?… https://t.co/aY70tEhJ5Y https://t.co/QaK1G7RJkp
Dr. John Cush RheumNow ( View Tweet)
🚨 Join us for the 7th Annual RheumNow Live 2/8 - 2/9 : Where Innovation Meets Impact in Rheumatology! 🚨
🗓 2025| In-Person & Virtual
💻 Virtual: Stream + Q&A access (spots still open!)
Don’t miss the rheumatology event of the year!
👉 Register today:… https://t.co/Rf4U6JcdKs https://t.co/ilG2M7aRYS
Dr. John Cush RheumNow ( View Tweet)
Quick study of Henoch-Schönlein Purpura (HSP) in Children: An Overview https://t.co/LPFFDIeJPA https://t.co/PlTD0fOR2E
Dr. John Cush RheumNow ( View Tweet)
Getting to Remission - Without Biologics
Analysis of data from two early rheumatoid arthritis (ERA) cohorts shows remission in RA is primarily seen in those who do not require biologic DMARDs (bDMARDs), while those needing bDMARDs are less apt to achieve remission.… https://t.co/knadKyxIpb https://t.co/OVSauZeetx
Dr. John Cush RheumNow ( View Tweet)
Proinflammatory Diet Increases Gout Risk
Some dietary habits are worse than others when it comes to gout risk for women, a large study indicated.
https://t.co/DS6JDfJZI4 https://t.co/U3Xwq96oGj
Dr. John Cush RheumNow ( View Tweet)
Epidemiology of idiopathic inflammatory myopathies (IIMs) has incidence rates ranging from 0.2 to 2 cases per 100 000 person-years. https://t.co/tUWpijtKWX https://t.co/Mb66cZ1Aga
Dr. John Cush RheumNow ( View Tweet)
Korean Study of 10,013 #SLE pts (91%F)those on immunosuppressives were not at greater risk for cancer. Total CA risk (n 368) was 59 per 10,000 PYs. Most common Thyroid, breast, Gastric, colon & cervical. https://t.co/R0s7ZXaUoX https://t.co/jAc5mgtmlm
Dr. John Cush RheumNow ( View Tweet)
QD clinics - lessons from the Clinic brought to you by RheumNow Live 2025
https://t.co/REMEN3gIjo https://t.co/P676QhAKwT
Dr. John Cush RheumNow ( View Tweet)
ACR Applauds Second Round of Medicare Drug Price Negotiations
The ACR applauded the announcement of additional drugs subject to pricing negotiations with the CMS. This second round includes nintedanib (Ofev) and apremilast (Otezla), which are used to treat common and rare… https://t.co/z1LkpWMXqg https://t.co/hqjkqTqJxw
Dr. John Cush RheumNow ( View Tweet)